[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"health-subjective\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:health-subjective":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,73,97,124,147,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100619495","phase-1-a-phase-i-randomized-double-blind-placebo-controlled-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-single-ascending-doses-of-sim0811-injection-in-healthy-chinese-adult-participants-100619495",false,"NCT07345364","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Participants","Inclusion Criteria:\n\n1. Healthy Chinese male or female adults aged 18 to 45 years (inclusive), not pregnant and not breastfeeding.\n2. Male participants weight ≥50 kg, female participants weight ≥45 kg, all ≤90 kg. Body Mass Index (BMI) between 19 and 26 kg\u002Fm² (inclusive). BMI = weight (kg) \u002F height² (m²).\n3. Female participants must avoid the menstrual period during the trial. participants of childbearing potential must commit to no plan for pregnancy, sperm\u002Fegg donation within 2 weeks before screening and for 6 months after the last dose, and voluntarily adopt highly effective contraception (including partner).\n4. Able to complete the study according to protocol requirements and commit to abstaining from smoking and alcohol during the trial.\n5. Prior to the trial, have fully understood the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial, voluntarily participate, can communicate well with the investigator, comply with all study requirements, and voluntarily sign the Ethics Committee-approved Informed Consent Form.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. History of drug allergy, or specific allergies (asthma, urticaria, eczema, etc.), or allergic constitution (e.g., allergy to two or more drugs, foods, pollen), or known allergy or significant intolerance to the investigational product or any of its components.\n2. Presence of clinically significant history of cardiovascular, respiratory, endocrine, urinary, digestive, hematological, neurological, skin, malignant tumor, infectious diseases, psychiatric disorders (e.g., seizures), metabolic abnormalities\u002Fdysfunction, etc.\n3. Screening physical examination, vital signs, laboratory tests, or other examination results judged by the clinician as abnormal with clinical significance (confirmed upon repeat assessment); OR presence of the following abnormal laboratory indicators: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total bilirubin, direct bilirubin, creatinine above the upper limit of normal (ULN); platelet count below the lower limit of normal (LLN); hyperkalemia, hypokalemia, hypercalcemia, or hypocalcemia judged by the investigator as abnormal and clinically significant; PT prolongation \\> ULN + 3s, TT prolongation \\> ULN + 3s, APTT prolongation \\> ULN + 10s, INR \\> 1.2, FIB \\\u003C 1.5 g\u002FL or \\> 4.0 g\u002FL, D-Dimer above ULN.\n4. Screening ECG findings judged as abnormal with clinical significance. Resting heart rate not within the range of 50 to 100 beats per minute (exclusive of boundaries). QTcF interval \\> 470 ms (QTcF = QT\u002F(RR)\\^0.33) or PR interval outside the range of 120 to 220 ms.\n5. Risk factors for Torsades de Pointes, or family history (first-degree relatives - biological parents, siblings, or children) of short QT syndrome, long QT syndrome, unexplained sudden death at a young age (≤40 years), drowning, or sudden infant death syndrome.\n6. Positive screening results for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, Treponema pallidum specific antibody, or Human Immunodeficiency Virus (HIV) antibody.\n7. Average daily alcohol consumption exceeding 2 units in the 2 years prior to screening, or weekly alcohol consumption \\>14 units (1 unit alcohol ≈ 360 ml beer or 45 ml 40% spirits or 150 ml wine); consumption of any alcohol-containing product within 24 hours prior to investigational product administration; or inability to stop alcohol consumption during the trial; or positive alcohol breath test.\n8. Average daily cigarette consumption \\>5 in the 2 years prior to screening, or inability to stop using any tobacco products during the trial.\n9. Positive screening result for drug abuse, or history of drug abuse or use of narcotics within the past five years.\n10. Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese herbal medicines, or health products within 2 weeks prior to screening and during screening, or within 5 half-lives of such drugs.\n11. Any surgery or trauma within 1 year prior to investigational product administration that may affect trial safety or drug disposition, and judged by the investigator to be of current clinical significance; OR planned surgery during the trial or within 7 days after trial completion.\n12. Difficulty with venous blood sampling, history of hematophobia or trypanophobia, or intolerance to indwelling venous catheter for blood sampling; OR history of phlebitis.\n13. Blood donation or blood loss \\>200 ml within 3 months prior to screening, or receipt of blood transfusion or blood products within 4 weeks; OR plan to donate blood during the trial or within 3 months after trial completion.\n14. History of blood abnormalities or related diseases, bleeding tendency, bleeding disorders (hemophilia, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.); OR arterial puncture at a site difficult to compress for hemostasis within 1 week prior; history of aneurysm.\n15. Pregnancy, lactation, positive pregnancy test, sexual intercourse without protocol-required contraception within 2 weeks prior to screening, or planned pregnancy.\n16. Vaccination within 1 month prior to screening, or planned vaccination during the trial \u002F within 2 weeks after the last investigational product dose.\n17. Participation in another drug or medical device clinical trial within 3 months prior to screening, or planned participation in another clinical trial during this study.\n18. Special dietary requirements and unable to accept unified diet and schedule arrangements.\n19. Other conditions judged by the clinical research physician as unsuitable for participation, or other reasons the participant may be unable to complete the study.",true,"ALL","18 Years","45 Years",{"count":20,"type":21},72,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study plans to set up 5 dose groups across 7 cohorts, including intravenous bolus plus infusion administration as well as intravenous bolus alone. The study plans to enroll 8 participants per cohort (investigational drug: placebo = 6:2), including both males and females, totaling 56 healthy participants. The study begins with dose-escalation enrollment starting from Cohort 1. Each cohort receives a single dose, sequentially completing Cohorts 2, 3, 4, 5, 6, and 7. After each cohort's dosing is completed, a 7-day observation period is conducted for safety evaluation. If the termination criteria are not met, the study may proceed to the next dose level following assessment by the Safety Review Committee. By collecting adverse events, as well as abnormal indicators from vital signs, electrocardiograms, and laboratory tests, and collecting blood samples at planned time points to measure SIM0811 plasma concentration and thrombotic molecular markers, the study aims to evaluate the tolerability and safety of SIM0811 injection in Chinese healthy adult participants, characterize its pharmacokinetic profile after single-dose administration, and explore the change curves of thrombotic molecular markers (plasmin-α2 antiplasmin complex PIC, fibrin degradation products FDP)",[27],"Health, Subjective","RECRUITING","2026-05-18",{"date":31,"type":32},"2026-05-20","ACTUAL",{"date":34,"type":32},"2026-01-12",{"date":36,"type":21},"2026-08-31",{"name":38,"class":39},"Jiangsu Simcere Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":15,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100627346","role-of-pro-resolving-lipid-mediators-in-obesity-associated-diseases-100627346","NCT07447440","Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases","Unraveling the Role of Pro-Resolving Lipid Mediators of Inflammation and Their Receptors in Obesity-Associated Diseases: New Therapeutic Approaches for Maresin 1 (RESOLBE)","RESOLBE","HEALTHY PARTICIPANTS:\n\nInclusion Criteria:\n\n* Postmenopause (al least 1 year).\n* Normoweight or overweight\u002Fobesity.\n* No personal history of cancer.\n* Stable weight over the last 3 months (±5%).\n* Willing to sign the informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Personal history of cancer.\n* Current weight loss treatment (diet, supplementation, surgery, others...).\n* Bariatric surgery.\n* No stable pharmacological treatment for at least 3 months.\n* Diabetes treatment and hormone replacement therapy.\n* Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.\n* High alcohol intake, more than 14 units per week for women and 20 units per week for men.\n* Surgical interventions resulting in permanent sequelae of the gastrointestinal tract.\n* Liver disease, except for non-alcoholic fatty liver disease.\n* Cognitive and\u002For psychiatric impairment.\n* Poor compliance or difficulty following study procedures.\n\nBREAST CANCER PARTICIPANTS:\n\nInclusion Criteria:\n\n* Postmenopause (at least 1 year).\n* Normoweight or overweight\u002Fobesity.\n* Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment.\n* Willing to sign the informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Luminal subtype breast cancer stages over than II or other type of breast cancer.\n* Require preoperative treatment.","FEMALE",{"count":51,"type":21},60,"OBSERVATIONAL","The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight\u002Fobesity.\n\nSpecific objectives are:\n\n* To analyse anthropometric and body composition changes.\n* To evaluate physical activity level.\n* To determine dietary profile.\n* To determine the adherence to Mediterranean dietary pattern.\n* To assess the quality of life.\n* To determine levels of specialized pro-resolving lipid mediators\n\nThe target sample size is 60 subjects. Participants will be allocated in four groups:\n\n* Group 1: Postmenopausal healthy women with overweight\u002Fobesity (n=15)\n* Group 2: Postmenopausal healthy women with normoweight (n=15)\n* Group 3: Postmenopausal women with breast cancer and overweight\u002Fobesity (n=15)\n* Group 4: Postmenopausal women with breast cancer and normoweight (n=15)",[55,27,56],"Breast Cancer","Obesity",[58,59,60,61,56],"Breast","Cancer","Postmenopause","Lipid mediators","2026-03-09",{"date":64,"type":32},"2026-03-11",{"date":66,"type":32},"2025-10-15",{"date":68,"type":21},"2027-12-30",{"name":70,"class":71},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":15,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":5},"100579837","florida-community-engaged-research-alliance-fl-ceal-100579837","NCT06829485","Florida Community-Engaged Research Alliance (FL-CEAL)","Inclusion Criteria:\n\n* Individuals living within the target community who do not plan to move out of the community within the next six months\n* Having two un-met SDOH needs\n\nSite Specific Inclusion Criteria:\n\nUniversity of Miami\u002F Healthy Little Havana Inclusion Criteria\n\n* Age 18 and over\n\nHealth Choice Network\u002F Broward Community Health Center\u002F Genesis Community Health Center Inclusion Criteria\n\n* Age 18 and over\n\nFlorida International University Inclusion Criteria -Latina Women Age 18 and over\n\nMayo Clinic Florida Inclusion Criteria\n\n-Age 21 and over\n\nFlorida A\\&M University\u002F Mother Care Network Inclusion Criteria\n\n* Female minors between the ages 11-14 years\n* Black\u002FAfrican American; Hispanic or Non-Hispanic ethnicity\n\nUniversity of Florida Inclusion Criteria\n\n* Women aged 18 and over\n* Pregnant and recently post-partum minority women\n\nExclusion Criteria:\n\n* Are unable or unwilling to consent\n* Plans to move out of the community during the next six months\n* Enrollment in a research study addressing Social Determinants Determinants Of Health (SDOH) in the last three years.\n* Prisoners","13 Years",{"count":81,"type":21},900,[83],"NA","The purpose of the study is learn more about ways to help people with non-medical issues that can affect participant health. The study team will examine if Community Health Workers, members of a community who provide basic health and medical care within communities, are more helpful to people with non-medical issues than simple reading materials on how participants can do it themselves.",[27],[87],"Health Determinants","2025-09-09",{"date":90,"type":32},"2025-09-11",{"date":92,"type":32},"2025-03-31",{"date":94,"type":21},"2028-12-01",{"name":96,"class":71},"University of Miami",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":107,"studyType":52,"phases":4,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100528206","gait-assessment-via-telephone-application-100528206","NCT06157749","Gait Assessment Via Telephone Application","Validity and Reliability of a Smartphone Application for Gait Assessment","Inclusion Criteria:\n\n* Age between 18 and 26 years.\n* Body Mass Index (BMI) within normal limits (18.5-24.9 kg\u002Fm2)\n\nExclusion Criteria:\n\n* Presence of lower extremity rotational problems (such as high femoral anteversion, internal tibial torsion, metatarsus adductus).\n* History of Botulinum Toxin Type A (BoNT-A) application or surgery within the last 6 months.\n* History of lower extremity injury within the last 6 months.\n* Leg length discrepancy.\n* Presence of third-degree pes planus.\n* Any neurological, rheumatic, musculoskeletal, metabolic, or connective tissue diseases.\n* History of pain, deformity, or surgery related to the vertebral column and upper extremities.\n* Presence of cognitive, mental, and\u002For severe psychiatric disorders","26 Years",{"count":106,"type":21},34,"1 Week","The evaluation of human gait is a crucial component of the clinical assessment and decision-making process. The gold standard in gait analysis is computerized gait analysis, which allows for three-dimensional digital data acquisition through computers (3D Computerized Gait Analysis). However, this technology is not readily accessible in routine analyses, as it proves to be a time-consuming and expensive endeavor in terms of infrastructure and human resources. The utilization of smartphones in clinical applications is on the rise, facilitated by the increasing accessibility of low-cost or free \"applications,\" thereby addressing the limitations associated with traditional gait analysis methods. The Gait-Analyzer application is among the mentioned applications. However, in the literature, no evidence has been found regarding the validity and reliability of Gait-Analyzer application compared to the gold standard 3D computerized gait analysis systems within the context of gait analyses.\n\nThe aim of this study is to comparatively examine the effectiveness of the Gait-Analyzer smartphone application with established 3D Computerized Gait Analysis systems, which have proven validity and reliability in gait analyses. Through this research, the study intends to elucidate the validity and reliability of spatiotemporal parameters of walking within the Gait-Analyzer smartphone application.",[27],[111,112,113,114],"3D Computerized Gait Analysis","Gait-Analyzer","Gait Analysis","Smartphone Application","2025-03-21",{"date":117,"type":32},"2025-03-24",{"date":119,"type":32},"2024-07-31",{"date":121,"type":21},"2025-09",{"name":123,"class":71},"Istanbul University - Cerrahpasa",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100553610","mulberry-leaf-extract-capsule-on-blood-glucose-control-in-healthy-volunteers-100553610","NCT06488326","Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteers","Effect of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteers","Inclusion Criteria:\n\n* Age 18-60 years\n* No diabetes mellitus\n* Have blood glucose less than 126 mg\u002FdL\n* Wiling to attend the study\n\nExclusion Criteria:\n\n* Take steroids, psychiatric medicine, thiazide diuretic medicine, and beta blocker medicine within 2 weeks before starting of the study\n* Take dietary supplement, herbal substance, and weight-loss medicine within 2 weeks before starting of the study\n* Uncontrolled diseases\n* History of gastrointestinal tract surgery\n* Liver and Kidney diseases\n* Pregnancy and lactation","60 Years",{"count":133,"type":21},56,[83],"Volunteers will be divided into 4 groups which are mulberry leaf extract 6 mg capsule, mulberry leaf extract 12 mg capsule, mulberry leaf extract 18 mg capsule, and placebo capsule group. They will be tested blood glucose levels (taken from the fingertips) before starting. Then, they will take 1 capsule of the sample one time. After taking the sample for 30 minutes, they will take 50 g of sucrose in 250 ml of water in 5 minutes. Then, they will be tested blood glucose levels (taken from the fingertips) at 30, 60, 90, and 120 minutes.",[27],"NOT_YET_RECRUITING","2024-06-28",{"date":140,"type":32},"2024-07-05",{"date":142,"type":21},"2024-07-01",{"date":144,"type":21},"2025-02-25",{"name":146,"class":71},"Chulalongkorn University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":40},"100327919","effects-of-patient-centered-telephone-education-in-day-surgery-100327919","NCT03549403","Effects of Patient-centered Telephone Education in Day Surgery","Effects of Patient-centered Pre- and Postoperative Telephone Education on the Experienced Health and Health-care Costs in Day Surgery by Adult Patients: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* arrive at the surgery from home\n* leave latest at the next morning of the surgery\n* leave home after surgery\n* is 18-64 years old\n* be able to respond to the questionnaire independently.\n\nExclusion Criteria:\n\n* over 65 years old patients\n* patients who need institutional care after surgery\n* patients who arrive to surgery from a institutional care unit","64 Years",{"count":156,"type":21},120,[83],"This study describe and evaluate the effectiveness of patient-centered telephone education in day surgery. The aim is to evaluate the effects of patient-centered telephone education on the experienced health of adult patients and the costs of healthcare in day surgery. Telephone education intervention is planned in co-operation with the day surgery unit´s healthcare staff.\n\nHalf of participants will receive current education in day surgery, while the other half will receive developed patient-centered telephone education before and after day surgery.",[27,160],"Cost Effectiveness",[162,163,164,165,166,167],"Telephone education","Effectiveness","Health","Cost","Day surgery","Adult patient","2023-11-28",{"date":170,"type":32},"2023-11-29",{"date":172,"type":21},"2024-09-01",{"date":174,"type":21},"2026-12",{"name":176,"class":71},"University of Oulu",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":49,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":40},"100399362","coping-after-breast-cancer---a-randomized-clinical-trial-with-two-digital-interventions-100399362","NCT04480203","Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions","Coping After Breast Cancer - CABC - Stressmestring Etter Brystkreft - SEB","CABC","Inclusion Criteria:\n\n* first occurrence breast cancer diagnosed from Jan 1, 2020\n* non-metastatic cancer stage 0-III\n\nInvasive tumors must be:\n\n* HER2 positive (regardless of ER, PR) or\n* ER negative\n* (may later include other ER+ if not conflict with recruitment for EMIT\u002FOPTIMA)\n\nExclusion Criteria:\n\n* None","20 Years","69 Years",{"count":188,"type":21},390,[83],"1. Breast cancer patients and age-matched controls are first invited to answer questions on HRQoL.\n2. Among responding breast cancer patients, a subset are invited in a randomized clinical trial with two digital interventions for cancer stress management, cognitive based stress management (CBSM) and mindfulness based intervention (MBI), as well as a control group.\n3. The goal is to determine whether digital CBSM or MBI can effectively reduce stress levels as compared to a control group. Second, whether these interventions can improve HRQoL (or avoid onset of HRQoL problems) for patients with breast cancer, compared to a control group.",[192,27],"Breast Cancer Patients",[194,195],"Health Related Quality of Life","Stress management intervention","2022-02-11",{"date":198,"type":32},"2022-03-02",{"date":200,"type":32},"2021-01-15",{"date":202,"type":21},"2035-12-31",{"name":204,"class":205},"Norwegian Institute of Public Health","OTHER_GOV"]